SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD

Review checklist: Robert Peary (HR-EX004)
All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments
Everything a reviewer needs to judge, gathered from the record. Release status: draft.
- 16judgment calls in the dossier
- 1protocol deviations
- 6orders and referrals without results in the record
- 1evidence items to check (retrospective or sensitive claims, unconfirmed diagnoses)
Review status
| Review | Status | Reviewer | Date | Notes |
|---|
| schema validation | not_started | | | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | | | Awaiting clinician review; check treatment before the antibody results, the intramuscular cyanocobalamin schedule and lifelong maintenance, the potassium check, no transfusion, the antibody tests drawn after the first injections, the endoscopy findings and three-year surveillance, iron deficiency after recovery, the neurological examination and its partial recovery, and the foot-care plan for old toe amputations. |
| provenance review | not_started | | | Sources: the Peary-MacMillan Arctic Museum (Bowdoin College) biography, Polar Pathways exhibit pages and Minik exhibit, Weems (Arctic 1982) and LeMoine (Arctic 2014) in full text, the University of New England finding aid for his daughter's papers, Arlington National Cemetery, and the Nobel Prize page. The roster's rheumatoid arthritis and psychological burden leads are not used as diagnoses. |
| safe messaging review | not_started | | | His bringing six Inughuit people to New York, four of whom died, and his two sons with an Inughuit woman are recorded plainly and respectfully as documented history; no health fact about any Inuit person is recorded, no descendant is named, and none has a role in the modern episode. Matthew Henson and the four Inughuit men are named only as documented companions. No relative is named or given a role in the modern episode. PHQ-9 6 and then 2 with item 9 scored 0, so no safety assessment is required. |
Judgment calls (dossier editorial resolutions)
- Sources. The case relies on the Peary-MacMillan Arctic Museum at Bowdoin College (biography, Polar Pathways exhibit pages and the Minik exhibit), Weems (1982) and LeMoine (2014) in the journal Arctic in full text, the University of New England finding aid for his daughter's papers, Arlington National Cemetery and the Nobel Prize page. The National Archives, Smithsonian and Library of Congress pages and the New York Times obituary were not read (not found, or access refused); the Social Networks and Archival Context and Archives Hub records could not be fetched. Contemporary wire reports found in searches (Papers Past and Utah Digital Newspapers) report that he died at home after an operation and that some thirty blood transfusions failed to save him; those pages could not be opened, so the transfusions are left out of the claims.
- Name. The display name is “Robert Peary”; his full name, “Robert Edwin Peary,” is the alias and appears in no other record. “Washington” appears only as a place (Washington, D.C.). No other figure with a record in the dataset is named.
- Index age and dates. The index visit on January 13, 2026 maps to January 13, 1919, when he was 62 and living in Washington, D.C., about a year before his death. The synthetic date of birth is May 6, 1963 (shift 107 years). The visits on January 21, February 3 and 17, March 10 and 24, and April 28, 2026 map to the same days of 1919, before his 63rd birthday and before the summer months he spent on Eagle Island. Past medical history includes only events up to 1899; claims about his death and about liver therapy are linked to the timeline at his death and are left out of the intake documents.
- Pernicious anemia (CLM-0013, D). His death from pernicious anemia is documented. When it began, how it was diagnosed and how it was treated are not documented in the sources read, so the modern episode's onset, timing and course are synthetic; the modern diagnosis is linked to the documented cause of death. Liver therapy, the first effective treatment, came only after his death (CLM-0014); the modern episode shows how the disease is treated now and does not imply that he could have been treated.
- Toes (CLM-0006, D; CLM-0007, R, disputed). Weems and LeMoine say he lost “most of his toes”; the roster says eight; LeMoine notes that the number and circumstances have been mythologized. The synthetic record gives toes two to five of each foot (eight toes, with both great toes kept) so that the ICD-10-CM codes Z89.421 and Z89.422 describe the feet exactly; this count is not a claim about the real number.
- Broken leg (CLM-0004). The museum exhibit says “both bones” broke “just above the ankle” but not which leg; the record does not say which leg.
- Inughuit people and his treatment of them (CLM-0003, CLM-0005, CLM-0008, CLM-0009). The Inughuit men and women who made the expeditions possible, the six people he brought to New York in 1897, four of whom died within months, and his two sons with an Inughuit woman are recorded plainly and with respect as documented history. No health fact about any Inuit person is recorded: the cause of death of the four people is left out, and nothing about the health of anyone at Fort Conger is taken from LeMoine's article. The four men of the 1909 polar party are named, with today's spellings, because the museum names them as companions; the Inughuit woman and the two sons are not named, and no descendant is named. None of them, and no relative, has any role, statement or decision in the modern episode.
- Relatives. His wife, children and mother appear only as documented history (marriage in 1888, two children, his mother raising him) and as “his wife” and “two adult children” in the social history. The advance care planning agent is unnamed and no relationship is given. No health fact about a relative is recorded beyond his father's early death, “cause not recorded in the cited source.”
- Roster leads not used. The roster's rheumatoid arthritis is not documented in any source read and is not a claim or a problem. The roster's “psychological burden of disputed legacy” is not used as a diagnosis; the documented dispute (CLM-0009, CLM-0010) appears in the social history, and his PHQ-9 is 6 at intake, mostly from fatigue, and 2 after treatment, with item 9 scored 0, so no safety assessment is required.
- Antibody timing. The intrinsic factor and parietal cell antibodies and gastrin were drawn at the consultation, after four injections, so that results first appear on the day the diagnosis is made. Some intrinsic factor antibody assays can be affected by recent high-dose cobalamin; the consultant follows the laboratory's guidance (NICE 1.4.3) and relies on the agreement of the parietal cell antibody, the gastrin and the biopsies. This is a judgment call for review.
- Clinical judgment calls. (1) Intramuscular cyanocobalamin started at intake, before the cause was known, because of neurological signs (BSH 2014, NICE 2024). (2) Cyanocobalamin every other day for seven doses, then weekly until neurological improvement levelled off at about fifteen weeks, then monthly for life; hydroxocobalamin, the BSH preparation, is less available in the United States. (3) High-dose oral therapy offered; he chose lifelong intramuscular maintenance, in line with NICE for autoimmune gastritis. (4) No transfusion at a hemoglobin of 8.2 g/dL with no symptoms at rest. (5) Upper endoscopy with Sydney-protocol biopsies at diagnosis, combined with a first screening colonoscopy; no neuroendocrine tumor or dysplasia; surveillance every three years by shared decision because of extensive atrophy and intestinal metaplasia (AGA 2021 advice 7, 8 and 10). NICE advises endoscopy only for new or worsening upper gastrointestinal symptoms; the case follows the AGA update. (6) TSH and thyroid antibody at diagnosis and TSH yearly; HbA1c with routine screening. (7) Iron deficiency unmasked at eight weeks, treated with alternate-day ferrous sulfate. (8) Foot care drawn from the IWGDF guideline for people with diabetes, applied to neuropathy from vitamin B12 deficiency in feet with old toe amputations; the falls recommendation is for adults 65 and older and is applied at 62 because of the neuropathy.
- Synthetic clinical picture. Everything in the modern episode is synthetic: every result, the smear, the endoscopy and pathology, the colonoscopy, the examination findings, the scores (PHQ-9, PHQ-2, MoCA, AUDIT-C, Timed Up and Go), the medicines and the outcomes. Height (183 cm, from Weems's “six-foot frame”) and weights are synthetic.
- Preventive visit. A periodic adult preventive visit at 62 (CPT 99396 with 99497 in plain text). Judgment calls: a lipid panel with a 10-year risk under 10 percent and no statin; colorectal screening up to date after the colonoscopy; PSA declined after shared decision-making; one-time HIV, hepatitis C and hepatitis B screening (negative, reported at fifteen weeks); recombinant zoster and PCV20 vaccines given; RSV vaccine not indicated without a risk condition; falls risk reviewed at every visit.
- Sick visit. A friction blister on the end of the left forefoot over the old amputation stump, from boots not yet broken in, chosen because it tests the plan: new sensory loss in feet that lost their toes long ago lets a blister go unnoticed, his daily foot check found it early, and offloading, fitted footwear and an earlier podiatry visit let it heal in two weeks. It is not a historical claim.
- Focused visits. The four chronic-care follow-ups (eight days with the consultation, five weeks with the endoscopy, eight weeks, fifteen weeks) are documented as focused visits on the CMID anemia monograph, the 2014 BSH cobalamin guideline, the 2024 NICE guideline, the 2021 AGA atrophic gastritis update, the IWGDF 2023 guideline, the USPSTF falls recommendation and the CMID depression monograph. One deviation is recorded instead of an invented result: the potassium planned with the second injection on day 3 was not drawn; no harm was evident (3.6 mmol/L at day 8 without cramps, weakness or palpitations, and 4.3 mmol/L at five weeks), and the corrective action was a repeat at the next visit and a standing order for potassium with any future loading course. Synthetic findings introduced: iron deficiency at eight weeks, the endoscopic and pathologic findings, and numbness at the ends of the feet that persists at fifteen weeks.
- Consultation. The hematology referral and the consultation by Marisol Abernethy-Kwan, MD (a fictional consultant), on the day of the eight-day visit, are S. The consultant answers the five referral questions in line with what the record shows afterwards: pernicious anemia confirmed by antibodies and gastrin; seven loading doses, weekly injections until recovery levels off, and monthly injections for life, with oral therapy as the alternative he declined; no transfusion, a repeat potassium (after the missed early check) and iron studies at eight weeks; endoscopy with Sydney-protocol biopsies and a colonoscopy, with surveillance set from the pathology; TSH yearly; and partial neurological recovery with foot protection and balance training.
Protocol deviations
Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.
| Visit | Measure | Interval | What happened |
|---|
2026-01-21 Progress note 02 (C-CDA) | Potassium | In the first days of treatment of severe anemia | The potassium planned with the second injection on day 3 was not drawn. Today it is 3.6 mmol/L, at the low end of normal, with no cramps, weakness or palpitations, so no harm is evident. Corrective action: potassium checked at the next visit, and a standing order for potassium added to any future loading course |
Orders and referrals without results in the record
| Visit | Type | Item | Status | Detail |
|---|
2026-01-21 Progress note 02 (C-CDA) | Examination | Upper endoscopy with Sydney-protocol biopsies for autoimmune gastritis, neuroendocrine tumors and dysplasia | Ordered | Booked with a screening colonoscopy in four weeks |
2026-01-21 Progress note 02 (C-CDA) | Referral | Podiatry | Ordered | Booked for the second week of February |
2026-01-21 Progress note 02 (C-CDA) | Referral | Physical therapy for balance and gait | Ordered | Starting next week |
2026-03-24 Progress note 06 (C-CDA) | Prevention | HIV screening | Ordered | Once for adults to 65; drawn today |
2026-03-24 Progress note 06 (C-CDA) | Prevention | Hepatitis C screening | Ordered | Once for all adults; drawn today |
2026-03-24 Progress note 06 (C-CDA) | Prevention | Hepatitis B screening | Ordered | Triple panel once for all adults; drawn today |
Evidence to check
Retrospective claims (R)
| Claim | Statement | Certainty |
|---|
| CLM-0007 | The number of toes he lost is uncertain: the roster says eight, and a historian of the expedition notes that the exact number and circumstances have been mythologized. | disputed |
Sensitive claims
None.
Diagnoses not confirmed
None.
Notes to read
Every note in the record, with its type. All clinical content is synthetic.
Abnormal results
| Date | Result | Value | Flag |
|---|
| 2026-01-13 | Hemoglobin | 8.2 g/dL (low) | Low |
| 2026-01-13 | MCV | 118 fL (high) | High |
| 2026-01-13 | RDW | 19.6% (high) | High |
| 2026-01-13 | White blood cells | 3.4 10*3/uL (low) | Low |
| 2026-01-13 | Platelets | 118 10*3/uL (low) | Low |
| 2026-01-13 | Reticulocytes | 0.4% (low) | Low |
| 2026-01-13 | LDH | 1240 U/L (high) | High |
| 2026-01-13 | Total bilirubin | 1.9 mg/dL (high) | High |
| 2026-01-13 | Vitamin B12 | 96 pg/mL (low) | Low |
| 2026-01-13 | Methylmalonic acid | 3.1 umol/L (high) | High |
| 2026-01-13 | Homocysteine | 38 umol/L (high) | High |
| 2026-01-13 | Transferrin saturation | 55% (high) | High |
| 2026-01-21 | Hemoglobin | 8.9 g/dL (low) | Low |
| 2026-01-21 | MCV | 114 fL (high) | High |
| 2026-01-21 | Reticulocytes | 7.9% (high) | High |
| 2026-01-21 | Intrinsic factor antibody | 38.5 [arb'U]/mL (high) | High |
| 2026-01-21 | Parietal cell antibody | 96 [arb'U]/mL (high) | High |
| 2026-01-21 | Gastrin (fasting) | 820 pg/mL (high) | High |
| 2026-02-17 | Hemoglobin | 12 g/dL (low) | Low |
| 2026-02-17 | MCV | 101 fL (high) | High |
| 2026-03-10 | RDW | 15.6% (high) | High |
| 2026-03-10 | Ferritin | 24 ng/mL (low) | Low |
| 2026-03-10 | Transferrin saturation | 14% (low) | Low |
| 2026-03-24 | LDL cholesterol (calculated) | 118 mg/dL (high) | High |